{'fraction_non_alphanumeric': 0.042232277526395176, 'fraction_numerical': 0.038461538461538464, 'mean_word_length': 4.744588744588745, 'pattern_counts': {'":': 0, '<': 1, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Role of TGFB1 as a biomarker in early HCC

Hepatocellular carcinoma (HCC) is the most common primary liver malignancy and is a leading cause of cancer-related death worldwide. Aim of the study to assess the value of transforming beta binding protein-1 in plasma as a biomarker for early detection of hepatocellular carcinoma in chronic hepatitis C infection. Patients and methods: This cross-sectional prospective, case-control hospital based study was conducted in Internal Medicine Department, Minia University Hospital in collaboration of our Radiology department and South Egypt Cancer Institute from June 2018 to June 2019. In this study included 90 subjects who were recruited from in patient and out -patient clinic and divided into three groups. Results: Simple logistic regression analysis of AFP and TGF-B1 for prediction of HCC among cirrhotic patients revealed that; increase TGF-B1by one unit will increase the risk of HCC by 3.7% (OR=1.037, 95%CI= 1.01-1.05, P value = 0.002), while; increase AFP by one unit will increase the risk of HCC by 2.7% (OR=1.027, 95%CI= 1.02-1.06, P value <0.001). Conclusion: We evaluated the serum levels of TGF-β1 in HCC patients, cirrhotic patient and normal subjects. Its aim was to determine the early prediction of hepatocellular carcinoma associated chronic hepatitis c virus.